BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

PFE upcoming catalysts

Pfizer: 10 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (7 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 26 readout(s) and 7 FDA event(s). Subscribe to PFE (.ics).

Drugs: Ritlecitinib, RSVpreF, VLA15, Fulvestrant, Encorafenib, Pembrolizumab, Pomalidomide, Dexamethasone, Rimegepant, Ritlecitinib higher, Ritlecitinib lower, Vepdegestrant, Palbociclib, Letrozole, PF-07104091 escalation, PF-07104091 expansion, Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, Binimetinib, Ribociclib, Elotuzumab, Bortezomib, Carfilzomib, Cetuximab, Glofitamab, Obinutuzumab, Daratumumab, enzalutamide

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-29 est.P3Pfizer PFENCT06641466 A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigraineMenstrual Migrainerecruiting723
2026-12-02 est.P3Pfizer PFENCT07029711 A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataSevere Alopecia Areataactive not recruiting208
2026-12-04 est.P3Pfizer PFENCT07500506 A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccineLyme Diseaserecruiting1712
2026-12-08 est.P2Pfizer PFENCT07228390 A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, HidradenitiHidradenitis Suppurativaactive not recruiting128
2026-12-25 est.P2Pfizer PFENCT07219615 A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.Chronic Spontaneous Urticariarecruiting200
2026-12-30 est.P3Pfizer PFENCT05909397 Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerBreast Canceractive not recruiting59
2026-12-31 est.P2Pfizer PFENCT04553133 PF-07104091 as a Single Agent and in Combination TherapySmall Cell Lung Cancer; Ovarian Cancer; Breast Canceractive not recruiting157
2026-12-31 est.P3Pfizer PFENCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingAdvanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumorsactive not recruiting77
2027-01-18 est.P3Pfizer PFENCT05035212 Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.Lower Respiratory Tract Illnessactive not recruiting38861
2027-01-25 est.P3Pfizer PFENCT07653100 A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFRespiratory Syncytial Virus (RSV)recruiting540

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-10-26FDA approvalapprovedPFIZER PFETALZENNAApproved 2026-10-26: TALZENNA (NDA217439 SUPPL4)
2026-10-26FDA approvalapprovedPFIZER PFETALZENNAApproved 2026-10-26: TALZENNA (NDA211651 SUPPL14)
2026-06-24FDA approvalapprovedPFIZER PFEIBRANCEApproved 2026-06-24: IBRANCE (NDA207103 SUPPL24)
2026-06-24FDA approvalapprovedPFIZER PFEIBRANCEApproved 2026-06-24: IBRANCE (NDA212436 SUPPL12)
2026-06-05FDA approvalapprovedPFIZER INC PFEHYMPAVZIApproved 2026-06-05: HYMPAVZI (BLA761369 SUPPL3)
2026-03-06FDA approvalapprovedPFIZER PFEXELJANZApproved 2026-03-06: XELJANZ (NDA213082 SUPPL13)
2026-03-06FDA approvalapprovedPFIZER PFEXELJANZApproved 2026-03-06: XELJANZ XR (NDA208246 SUPPL27)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-12 est.P2Pfizer PFENCT05995964 A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisAtopic Dermatitisactive not recruiting507
2026-10-30 est.P3Pfizer PFENCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaMelanomaactive not recruiting257
2026-10-09P2Pfizer PFENCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical StuPulmonary Hypertensionterminated42
2026-10-06P1/P2Pfizer PFENCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-StBreast Cancerterminated20
2026-09-29P1/P2Pfizer PFENCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesObesity and Obesity-related Medical Conditionscompleted201
2026-09-23P2Pfizer PFENCT05070845 Safety and Efficacy Study of PF-06835375 in Primary Immune ThrombocytopeniaPrimary Immune Thrombocytopeniaterminated61
2026-09-10P1/P2Pfizer PFENCT06125522 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-SBreast Cancerterminated11
2026-08-26P3Pfizer PFENCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other TreatmentMultiple Myelomarecruiting492
2026-08-25P3Pfizer PFENCT07543380 A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.Respiratory Syncytial Virus (RSV)completed130
2026-07-31P1/P2Pfizer PFENCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial HypertensionPulmonary Arterial Hypertensioncompleted97
2026-07-30 est.P3Pfizer PFENCT05261139 EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not HoCOVID-19recruiting160
2026-07-23P2Pfizer PFENCT03307980 Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia BHemophilia Bterminated21
2026-06-19P2Pfizer PFENCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic ColorectaMetastatic Colorectal Canceractive not recruiting108
2026-05-12P1/P2Pfizer PFENCT06182124 A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsPneumococcal Diseasecompleted1710
2026-04-09P1/P2Pfizer PFENCT05896163 A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B-Cell Lymphomaterminated40
2026-02-26P3Pfizer PFENCT05020236 A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsMultiple Myelomarecruiting893
2026-02-18P3Pfizer PFENCT04821622 Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCProstate Canceractive not recruiting599
2026-02-09P2Pfizer PFENCT06531538 A Study to Learn About How a New Pneumococcal Vaccine Works in ChildrenPneumococcal Diseasecompleted225
2026-02-05P3Pfizer PFENCT05583526 A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) TranquilloStable Nonsegmental Vitiligo; Active Nonsegmental Vitiligocompleted607
2026-02-02P2Pfizer PFENCT05926960 A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaMelanomaterminated38
2026-01-12P2Pfizer PFENCT06105632 A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic BrAdvanced or Metastatic Breast Canceractive not recruiting333
2026-01-07P3Pfizer PFENCT05477524 An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)Lyme Diseasecompleted12546
2025-12-29P2Pfizer PFENCT06897202 A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DMObesity in Diabetes; Type 2 Diabetes Mellitus (T2DM)completed133
2025-12-22P3Pfizer PFENCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermDermatitis, Atopiccompleted3166
2025-12-16P2Pfizer PFENCT06973720 A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or OverweightObesity; Overweight or Obesitycompleted268
2025-12-16P2Pfizer PFENCT04821310 Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 YearsEsophagitisterminated43

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.